KR102294405B1 - 항-섬유형성 화합물, 방법 및 이의 용도 - Google Patents

항-섬유형성 화합물, 방법 및 이의 용도 Download PDF

Info

Publication number
KR102294405B1
KR102294405B1 KR1020167000203A KR20167000203A KR102294405B1 KR 102294405 B1 KR102294405 B1 KR 102294405B1 KR 1020167000203 A KR1020167000203 A KR 1020167000203A KR 20167000203 A KR20167000203 A KR 20167000203A KR 102294405 B1 KR102294405 B1 KR 102294405B1
Authority
KR
South Korea
Prior art keywords
delete delete
kynurenine
fibrosis
expression
mmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167000203A
Other languages
English (en)
Korean (ko)
Other versions
KR20160018676A (ko
Inventor
아지즈 게하리
윤유안 리
티. 킬라니 루핸기즈
라이언 하트웰
Original Assignee
더 유니버시티 오브 브리티쉬 콜롬비아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 유니버시티 오브 브리티쉬 콜롬비아 filed Critical 더 유니버시티 오브 브리티쉬 콜롬비아
Publication of KR20160018676A publication Critical patent/KR20160018676A/ko
Application granted granted Critical
Publication of KR102294405B1 publication Critical patent/KR102294405B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020167000203A 2013-06-05 2014-06-04 항-섬유형성 화합물, 방법 및 이의 용도 Active KR102294405B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361831404P 2013-06-05 2013-06-05
US61/831,404 2013-06-05
PCT/CA2014/000484 WO2014194407A1 (en) 2013-06-05 2014-06-04 Anti-fibrogenic compounds, methods and uses thereof

Publications (2)

Publication Number Publication Date
KR20160018676A KR20160018676A (ko) 2016-02-17
KR102294405B1 true KR102294405B1 (ko) 2021-08-25

Family

ID=52007349

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167000203A Active KR102294405B1 (ko) 2013-06-05 2014-06-04 항-섬유형성 화합물, 방법 및 이의 용도

Country Status (14)

Country Link
US (1) US9737523B2 (https=)
EP (1) EP3003298B1 (https=)
JP (1) JP6473938B2 (https=)
KR (1) KR102294405B1 (https=)
AU (1) AU2014277568B2 (https=)
CA (1) CA2914261C (https=)
DK (1) DK3003298T3 (https=)
ES (1) ES2978920T3 (https=)
PH (1) PH12015502717B1 (https=)
PL (1) PL3003298T3 (https=)
RU (1) RU2726416C2 (https=)
SG (1) SG11201510003VA (https=)
WO (1) WO2014194407A1 (https=)
ZA (1) ZA201600015B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10779517B2 (en) 2017-01-31 2020-09-22 The Board Of Regents Of The University Of Oklahoma Animal wound model and methods of use
CN112168822B (zh) * 2020-09-27 2022-11-08 集美大学 犬尿酸在改善高脂饮食致血脂异常、肥胖、肠道菌群混乱中的用途
JP2024517463A (ja) * 2021-05-04 2024-04-22 ソヴィダ ソリューションズ リミテッド ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法
WO2022232950A1 (en) * 2021-05-07 2022-11-10 Birchbiomed Inc. Kynrenine and derivatives thereof for treating atrophic scarring
CN119055650A (zh) * 2024-09-06 2024-12-03 上海市东方医院（同济大学附属东方医院） 犬尿喹啉酸在治疗慢性肝硬化中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008087461A2 (en) * 2007-01-17 2008-07-24 Szegedi Tudományegyetem Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1369114A1 (en) * 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
EP1824469A4 (en) * 2004-11-17 2008-07-30 Nuon Therapeutics Pty Ltd METHOD FOR MODULATING B-CELL FUNCTION
JP6855165B2 (ja) * 2012-06-15 2021-04-07 コナリス リサーチ インスティチュート アーゲー ニコチン酸および／もしくはニコチンアミドならびに／またはトリプトファンを含有する、腸内微生物叢によい影響を及ぼすための医薬組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008087461A2 (en) * 2007-01-17 2008-07-24 Szegedi Tudományegyetem Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis

Also Published As

Publication number Publication date
CA2914261A1 (en) 2014-12-11
US20160120857A1 (en) 2016-05-05
BR112015030569A2 (pt) 2017-07-25
DK3003298T3 (da) 2024-06-17
PH12015502717A1 (en) 2016-03-14
PL3003298T3 (pl) 2024-07-15
RU2015156196A3 (https=) 2018-05-24
AU2014277568B2 (en) 2019-09-19
AU2014277568A1 (en) 2016-01-28
JP2016521695A (ja) 2016-07-25
WO2014194407A1 (en) 2014-12-11
US9737523B2 (en) 2017-08-22
ZA201600015B (en) 2019-07-31
JP6473938B2 (ja) 2019-02-27
PH12015502717B1 (en) 2023-09-13
CA2914261C (en) 2020-02-11
RU2726416C2 (ru) 2020-07-14
RU2015156196A (ru) 2017-07-14
NZ715579A (en) 2021-05-28
EP3003298A4 (en) 2017-03-22
EP3003298B1 (en) 2024-03-20
ES2978920T3 (es) 2024-09-23
EP3003298A1 (en) 2016-04-13
SG11201510003VA (en) 2016-01-28
BR112015030569A8 (pt) 2020-01-07
KR20160018676A (ko) 2016-02-17

Similar Documents

Publication Publication Date Title
Wang et al. E2F2 directly regulates the STAT1 and PI3K/AKT/NF-κB pathways to exacerbate the inflammatory phenotype in rheumatoid arthritis synovial fibroblasts and mouse embryonic fibroblasts
Luo et al. Suppression of SMOC2 reduces bleomycin (BLM)-induced pulmonary fibrosis by inhibition of TGF-β1/SMADs pathway
Li et al. Kynurenine increases matrix metalloproteinase-1 and-3 expression in cultured dermal fibroblasts and improves scarring in vivo
Liu et al. Wnt/β-catenin pathway forms a negative feedback loop during TGF-β1 induced human normal skin fibroblast-to-myofibroblast transition
KR102294405B1 (ko) 항-섬유형성 화합물, 방법 및 이의 용도
Wang et al. Apelin attenuates TGF-β1-induced epithelial to mesenchymal transition via activation of PKC-ε in human renal tubular epithelial cells
Raman et al. Integrin-linked kinase signaling promotes cyst growth and fibrosis in polycystic kidney disease
Roy et al. Role of MrgprB2 in rosacea-like inflammation in mice: modulation by β-arrestin 2
Huang et al. A novel caffeic acid derivative prevents renal remodeling after ischemia/reperfusion injury
Hammoud et al. Deficiency in TIMP-3 increases cardiac rupture and mortality post-myocardial infarction via EGFR signaling: beneficial effects of cetuximab
JP2017061539A (ja) Ｂｃａｔ１阻害剤を使用する治療方法
Riaz et al. Anti-hypertrophic effect of Na+/H+ exchanger-1 inhibition is mediated by reduced cathepsin B
US20230193276A1 (en) Composition of drug targets and method of using thereof
JP7297104B2 (ja) 特発性肺線維症の動物モデル、その構築方法及び使用
KR20180010245A (ko) 저산소증 신호전달 유전자를 저해하기 위한 ape1/ref-1을 표적화하는 방법
JP2022535797A (ja) 特発性肺線維症の薬剤標的
Yang et al. Vitamin D alleviates silica-induced pulmonary fibrosis partly by inhibiting STAT3/hexokinase 2-mediated fibroblast glycolysis
NZ715579B2 (en) Anti-fibrogenic compounds, methods and uses thereof
KR20190091621A (ko) 벤조[d]싸이아졸 유도체 또는 이의 염을 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물
KR20210147411A (ko) 면역 세포 활성화를 통한 암 치료를 위한 RORα의 용도
BR112015030569B1 (pt) Uso de compostos anti-fibrogênicos
TWI919263B (zh) 預防或治療骨關節炎的凝血調節素與ｍｉＲＮＡ
Li et al. The role of TRPC6-mediated autophagy in myocardial ischaemia/reperfusion injury
Lei et al. Macrophage SIRT6 promotes allergic airway inflammation through ATG3 deacetylation-mediated autophagy
Shen et al. Pin1 Regulates IL-5 Induced Eosinophil Polarization and Migration. Cells 2021, 10, 211

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160105

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190604

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200914

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210315

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210621

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210820

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210820

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240722

Start annual number: 4

End annual number: 4